SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently facing intense selling pressure, with the stock sliding toward 52-week lows amid a broader cooling of software sector valuations. Investors are actively debating whether this is a structural breakdown or a temporary sentiment reset, with many highlighting the tension between the company's strong revenue growth and concerns over its high valuation multiples.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion Inc. is trending following the White House's announcement of new executive orders focused on quantum sensing and networking, which positions the company as a key beneficiary in the quantum sector. Investors are actively discussing the stock's long-term potential, its upcoming Russell 3000 inclusion, and the impact of government-backed quantum initiatives on the broader technology landscape.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors debate the impact of leadership changes, including the upcoming departure of the CFO, while closely monitoring progress in the company's oncology pipeline following recent trial updates. Market participants are actively discussing the stock's long-term valuation and the effectiveness of current growth strategies in the competitive biotech landscape.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is experiencing heightened investor interest driven by positive Phase 3 data for its MDD therapeutic and anticipation of a series of upcoming pivotal trial milestones. The community is actively debating the company's long-term commercialization prospects and the impact of a recent major public offering, with many investors weighing the potential for a breakthrough against the risks of dilution and the competitive landscape for psychedelic-based medicine.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to the company's roadmap for gate-model quantum simulators and potential expansion into government-backed quantum initiatives. The community remains highly polarized, with intense debate between long-term bulls betting on quantum supremacy and skeptics focused on high cash burn, heavy insider selling, and extreme valuation concerns.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is seeing intense investor attention and increased trade volume following a significant purchase order for its NeuraWave photonic reservoir systems and broader sector momentum surrounding government-led quantum technology initiatives. The community remains highly focused on the company's hardware commercialization progress and the potential for a short squeeze, given the substantial short interest and heavy call option activity.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant investor interest as shareholders bet on a long-term turnaround fueled by international expansion, a new CEO, and persistent buyout speculation involving major stakeholders. The community remains heavily focused on the stock's elevated short interest, with many retail traders actively discussing the potential for a short squeeze despite ongoing concerns regarding operational efficiency and food quality.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting significant retail and institutional interest as investors track substantial share accumulation by CEO Kevin Tang and speculate on a potential buyout. While the company maintains clinical progress and steady commercial performance, the community remains divided, weighing the upside of recent insider activity against long-standing frustration over management transparency and sluggish price movement.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending due to the convergence of an upcoming earnings report and the high-profile IPO of its partner Cerebras, sparking investor interest in its specialized data center and AI compute infrastructure model. The community is actively discussing the stock's low float and the potential for a valuation re-rate as it aligns with broader AI capacity demand.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing significant selling pressure, pushing shares to new lows and sparking a heated debate between traders who view the stock as deeply oversold value and those who argue that fading content momentum and weak sentiment justify further downside. The community is focused on the lack of stabilization at key technical support levels, with many traders expressing frustration over executive performance and the absence of aggressive share buybacks despite massive authorized capital.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.

Madrigal Pharmaceuticals Q1 Earnings Call Highlights

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 net sales of $311.3 million as executives said demand for its MASH therapy Rezdiffra continued to build in a market they described as still early in development. On the company's earnings call, management highlighted patient growth...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $620.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday...

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +9.97% and +3.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Madrigal Pharmaceuticals Posts Wider Loss In Q1

(RTTNews) - Wednesday, Madrigal Pharmaceuticals, Inc. (MDGL) announced its first-quarter financial results, reporting a net loss of $94.4 million, or $3.25 a share, compared to $73.2 million, or $2.61 a share, in the previous year...

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...

Vanguard Group Inc. Trims Stake in Madrigal Pharmaceuticals, Inc. $MDGL

Vanguard Group Inc. reduced its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 0.2% in the fourth quarter, according to its most recent 13F filing with the...

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MDGLMadrigal Pharmaceuticals Inc

Fundamentals

Latest MDGL News